EMA: Response to TB CAB letter

European Medicines Agency
July 8, 2012, 10:29 a.m.
post image

EMA's response to TB CAB letter regarding conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783).

Download the letter from here.